Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Operating Leases (2019 - 2025)

BioNexus Gene Lab's Operating Leases history spans 7 years, with the latest figure at $126943.0 for Q3 2025.

  • For Q3 2025, Operating Leases rose 401.02% year-over-year to $126943.0; the TTM value through Sep 2025 reached $126943.0, up 401.02%, while the annual FY2024 figure was $210557.0, 57.84% up from the prior year.
  • Operating Leases for Q3 2025 was $126943.0 at BioNexus Gene Lab, down from $141347.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $210557.0 in Q4 2024 and bottomed at $14118.0 in Q3 2022.
  • The 5-year median for Operating Leases is $42909.0 (2021), against an average of $80773.2.
  • The largest annual shift saw Operating Leases skyrocketed 642.79% in 2023 before it crashed 75.84% in 2024.
  • A 5-year view of Operating Leases shows it stood at $42909.0 in 2021, then soared by 32.31% to $56775.0 in 2022, then surged by 134.95% to $133395.0 in 2023, then surged by 57.84% to $210557.0 in 2024, then tumbled by 39.71% to $126943.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Operating Leases are $126943.0 (Q3 2025), $141347.0 (Q2 2025), and $200113.0 (Q1 2025).